Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cardiac Cycle

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    291 result(s) found for: Cardiac Cycle. Displaying page 1 of 15.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2017-001094-16 Sponsor Protocol Number: PROACT Start Date*: 2017-08-08
    Sponsor Name:South Tees NHS Foundation Trust
    Full Title: Preventing cardiac damage in patients treated for breast cancer and lymphoma: a phase 3 Randomised, Open label, blinded endpoint, trial of enalapril to prevent Anthracycline-induced CardioToxicity ...
    Medical condition: Prevention of cardiotoxicity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10007541 - Cardiac disorders 10048610 Cardiotoxicity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2015-002265-36 Sponsor Protocol Number: CHDR1518 Start Date*: 2015-10-22
    Sponsor Name:Centre for Human Drug Research
    Full Title: A randomized, double blind, crossover, placebo controlled class-room experiment to assess the pharmacodynamics and pharmacokinetics of metoprolol in healthy volunteers with different polymorphism o...
    Medical condition: Influence of CYP2D6 polymorphism on metoprolol pharmacokinetics and pharmacodynamics in human volunteers
    Disease: Version SOC Term Classification Code Term Level
    18.0 10007541 - Cardiac disorders 10007521 Cardiac arrhythmias HLGT
    18.0 10047065 - Vascular disorders 10015488 Essential hypertension PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2004-004225-10 Sponsor Protocol Number: 3001081 Start Date*: 2005-03-07
    Sponsor Name:Orion Pharma
    Full Title: Effects of peroral levosimendan in the prevention of further hospitalisations in patients with chronic heart failure. A randomised, double-blind, placebo-controlled, multi-centre, parallel-group study
    Medical condition: Cardiac Failure
    Disease: Version SOC Term Classification Code Term Level
    7.1 10007554 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Completed) LT (Completed) LV (Completed) EE (Completed)
    Trial results: View results
    EudraCT Number: 2016-004267-40 Sponsor Protocol Number: MIT-Es0001-C202 Start Date*: 2017-01-16
    Sponsor Name:Estetra SPRL
    Full Title: A SINGLE-CENTER, RANDOMIZED, OPEN-LABEL, TWO-ARM STUDY TO EVALUATE THE OVARIAN FUNCTION INHIBITION OF A MONOPHASIC COMBINED ORAL CONTRACEPTIVE (COC) CONTAINING 15 MG ESTETROL (E4) AND 3 MG DROSPIRE...
    Medical condition: Hormonal contraception in woman seeking contraception
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004865 10073728 Hormonal contraception LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2016-002270-12 Sponsor Protocol Number: TRIMETA Start Date*: 2016-10-20
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
    Full Title: Clinical trial phase II, prospective, open, randomized, controlled study to evaluate the preventive effect of trimetazidine on the cardiotoxicity of trastuzumab and chemotherapy in patients with br...
    Medical condition: BREAST CANCER
    Disease: Version SOC Term Classification Code Term Level
    23.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER2 positive breast cancer PT
    Population Age: Adults Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-005208-24 Sponsor Protocol Number: hCG-GR-001-2016 Start Date*: 2017-07-12
    Sponsor Name:Prof. Harry Siristatidis
    Full Title: A prospective, multicenter, double-blind, randomized, placebo-controlled, two-parallel groups Phase IIIb clinical study, to assess the efficacy and safety of adding low doses of hCG at a short IVF ...
    Medical condition: Infertility
    Disease: Version SOC Term Classification Code Term Level
    20.0 10038604 - Reproductive system and breast disorders 10021928 Infertility female PT
    Population Age: Adults Gender: Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-001685-29 Sponsor Protocol Number: CV013-011 Start Date*: 2017-05-17
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, Dose-Ranging, Phase 2b Study of the Safety and Efficacy of Continuous 48-Hour Intravenous Infusions of BMS-986231 in Hos...
    Medical condition: Heart failure and impaired systolic function
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10074631 Systolic heart failure LLT
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) CZ (Completed) NL (Completed) GB (Completed) GR (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2013-004333-33 Sponsor Protocol Number: 13HH1771 Start Date*: 2014-01-20
    Sponsor Name:Imperial College London
    Full Title: Phase 1 of dose escalation of extracorporeal shockwave treatment only and in combination DPP-4 inhibitor and parathyroid hormone (non-randomised, open-labelled) & Phase II of combination treatments...
    Medical condition: ischaemic cardiomyopathy
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10077980 Chronic systolic heart failure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2021-002346-33 Sponsor Protocol Number: MO43110 Start Date*: 2022-05-17
    Sponsor Name:Roche Farma S. A. U. que realiza el ensayo en España y que actúa como representante F. Hoffmann-La Roche Ltd
    Full Title: A PHASE IIIB, MULTINATIONAL, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY TO EVALUATE PATIENT PREFERENCE FOR HOME ADMINISTRATION OF FIXED-DOSE COMBINATION OF PERTUZUMAB AND TRASTUZUMAB FOR SUBCUTANEOU...
    Medical condition: Early or locally advanced/inflammatory HER2-positive (HER2+) breast cancer.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) BG (Ongoing) HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2021-002639-48 Sponsor Protocol Number: 54767414AMY2009 Start Date*: 2022-07-25
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Phase 2, Multicohort Study of Daratumumab-Based Therapies in Participants with Amyloid Light Chain (AL) Amyloidosis
    Medical condition: Amyloid Light Chain Amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    23.0 100000004870 10083938 Amyloid light-chain amyloidosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Trial now transitioned) ES (Ongoing) IT (Ongoing) NL (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-002248-26 Sponsor Protocol Number: IEOS701/412 Start Date*: 2012-10-16
    Sponsor Name:ISTITUTO EUROPEO DI ONCOLOGIA
    Full Title: Prevention of anthracycline-induced cardiotoxicity: a multicentre randomizedtrial comparing two therapeutic strategies.
    Medical condition: Anthracycline-­‐induced cardiotoxicity
    Disease: Version SOC Term Classification Code Term Level
    14.1 10042613 - Surgical and medical procedures 10008444 Chemotherapy cardiotoxicity attenuation PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003586-26 Sponsor Protocol Number: CV013-020 Start Date*: 2018-06-12
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Multicenter, Randomized, Double-Blind, Placebo- and Active-Controlled, Cross-over Phase 2 Study of Continuous 5-Hour Intravenous Infusions of BMS-986231 in Patients with Heart Failure and Impaire...
    Medical condition: Heart failure and impaired systolic function
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004849 10074631 Systolic heart failure LLT
    20.0 100000004849 10019279 Heart failure LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2013-000123-13 Sponsor Protocol Number: ML28794 Start Date*: 2013-08-28
    Sponsor Name:NV ROCHE SA
    Full Title: A single arm multi-center study investigating the at home administration of trastuzumab subcutaneous vial for the treatment of patients with HER2-positive early breast cancer
    Medical condition: TO INVESTIGATE THE AT HOME ADMINISTRTATION OF TRASTUZUMAB SUBCUTANEOUS VIAL FOR THE TREATMENT OF PATIENTS WITH HER2-POSITIVE EARLY BREAST CANCER.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000276-23 Sponsor Protocol Number: 201464 Start Date*: 2016-12-06
    Sponsor Name:GlaxoSmithKline Research & Development Ltd
    Full Title: A multiple treatment session, open label phase 2 clinical study of GSK2398852 administered following and together with GSK2315698 in cohorts of patients with cardiac amyloidosis
    Medical condition: Systemic amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10021428 Immune system disorders SOC
    20.0 10021428 - Immune system disorders 10002022 Amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003976-11 Sponsor Protocol Number: HSG-1-13 Start Date*: 2014-01-24
    Sponsor Name:Helsinki University Central Hospital
    Full Title: Effects of S-1 and capecitabine in combination with oxaliplatin on the coronary artery blood flow in patients metastatic gastrointestinal tract adenocarcinoma
    Medical condition: Metastatic gastrointestinal tract adenocarcinoma
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FI (Prematurely Ended) DK (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-004897-32 Sponsor Protocol Number: WO40324 Start Date*: 2018-06-04
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A phase III, randomized, multicenter, open-label, two-arm study to evaluate the pharmacokinetics, efficacy, and safety of subcutaneous administration of the fixed-dose combination of pertuzumab and...
    Medical condition: Human epidermal growth factor receptor 2 (HER2)-positive Early Breast Cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) ES (Ongoing) BE (Completed) CZ (Completed) PL (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2008-002322-11 Sponsor Protocol Number: ARTemis Start Date*: 2009-04-29
    Sponsor Name:Cambridge University Hospitals NHS Foundation Trust [...]
    1. Cambridge University Hospitals NHS Foundation Trust
    2. University of Cambridge
    Full Title: ARTemis : Avastin® Randomised Trial with nEo-adjuvant cheMotherapy for patients wIth early breaSt cancer
    Medical condition: HER2 negative invasive breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2018-003857-73 Sponsor Protocol Number: D6130C00003 Start Date*: 2019-09-26
    Sponsor Name:AstraZeneca AB
    Full Title: A Phase I/II, Open-Label, Multicentre 2-Part Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 as Monotherapy or in Combination in Treatment-Naïve or Relapsed/Refr...
    Medical condition: Treatment Naïve or Relapsed/Refractory Acute Myeloid Leukemia
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2016-001965-98 Sponsor Protocol Number: PGFN-001 Start Date*: 2017-01-10
    Sponsor Name:Prolong Pharmaceuticals, LLC
    Full Title: A randomized and open-label dose-finding, phase 2, efficacy, safety, and pharmacokinetic study of once-per-cycle prophylactic injections of ANF-RHO™ versus pegfilgrastim (Neulasta®) in non-metastat...
    Medical condition: chemotherapy-induced neutropenia (CIN)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10076734 Chemotherapy induced neutropenia LLT
    Population Age: Adults Gender: Female
    Trial protocol: NL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2018-002761-19 Sponsor Protocol Number: OP201 Start Date*: 2019-10-21
    Sponsor Name:Oncopeptides AB
    Full Title: An Open-Label, Phase 1/2 Study of Melflufen and Dexamethasone for Patients with AL Amyloidosis Following at Least One Prior Line of Therapy
    Medical condition: Patients with AL Amyloidosis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021428 - Immune system disorders 10002022 Amyloidosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Ongoing) NO (Prematurely Ended) PL (Prematurely Ended) ES (Prematurely Ended) DE (Prematurely Ended) GR (Completed) IT (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat May 18 10:28:14 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA